Background: GLP-1 RAs are widely used for T2DM treatment due to their cardiorenal and metabolic benefits. This study examines the risk of pancreatic cancer with GLP-1 RA use in patients with T2DM. Methods: We analyzed TriNetX’s deidentified research database using the U.S. Collaborative Network comprising 62 healthcare organizations across the U.S.A. Patients with T2DM were split into two cohorts: one receiving GLP-1 RAs, and one not receiving GLP-1 RAs. We excluded patients with known risk factors for pancreatic cancer, including pancreatic cysts, a personal or family history of BRCA1, BRCA2, CDKN2A, KRAS, MEN1, MLH1, MSH2, NOTCH1, PALB2, PMS2, and PRSS1S genes, family history of pancreatic cancer, and VHL syndrome. Using a 1:1 propensity score-matching model based on baseline characteristics and comorbidities, we created comparable cohorts. We then compared the rate of pancreatic cancer between the two cohorts at a 7-year interval. Results: Out of 7,146,015 identified patients with T2DM, 10.3% were on a GLP-1 RA and 89.7% were not. Post-PSM, 721,110 patients were in each group. Patients on GLP-1 RAs had a 0.1% risk compared to a 0.2% risk of pancreatic cancer in the 7-year timeframe. Conclusion: The use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) does not appear to substantially elevate the risk of pancreatic cancer; in fact, it may potentially exert a protective effect.
背景：胰高血糖素样肽-1受体激动剂因其心肾及代谢获益被广泛应用于2型糖尿病治疗。本研究旨在探讨2型糖尿病患者使用GLP-1受体激动剂与胰腺癌风险的相关性。方法：我们通过覆盖全美62家医疗机构的美国协作网络，分析了TriNetX去识别化研究数据库。将2型糖尿病患者分为两组：接受GLP-1受体激动剂治疗组与未接受治疗组。排除已知胰腺癌风险因素患者，包括胰腺囊肿、个人或家族BRCA1、BRCA2、CDKN2A、KRAS、MEN1、MLH1、MSH2、NOTCH1、PALB2、PMS2及PRSS1S基因突变史、胰腺癌家族史以及VHL综合征。采用基于基线特征与合并症的1:1倾向评分匹配模型构建可比队列，随后比较两组患者在7年观察期内胰腺癌发生率。结果：在7,146,015例2型糖尿病患者中，10.3%使用GLP-1受体激动剂，89.7%未使用。倾向评分匹配后两组各纳入721,110例患者。7年观察期内，GLP-1受体激动剂治疗组胰腺癌风险为0.1%，而未治疗组为0.2%。结论：在2型糖尿病患者中使用GLP-1受体激动剂并未显著增加胰腺癌风险，反而可能具有潜在保护作用。
肿瘤(癌症)患者之家